OBJECTIVE: The aim of this study was to evaluate the utility of the @entity3503 beam coagulator (ABC) in achieving optimal (< or =1 cm) disease status and facilitating the conversion of optimal but visible disease (0.1-1.0 cm) to microscopic @entity66 (complete cytoreduction) among @entity1 with advanced @entity43 . METHODS: All @entity1 undergoing their primary attempt at surgical cytoreduction for Stage IIIB-IV @entity43 between October 1, 1997 and June 30, 2000 were identified from the @entity5 registry database. Data were abstracted retrospectively and included: the size/location of precytoreduction disease, surgical procedures performed, the anatomic regions in which the ABC was used for cytoreduction, the size/location of @entity41 , and the date of last follow-up and disease status. Survival curves were generated using the Kaplan-Meier method, and statistical comparisons were performed using the chi(2) test, Fisher's exact test, log rank test, and multivariate logistic regression. RESULTS: Forty-five @entity1 were identified (FIGO Stage IIIB = 8, Stage IIIC = 29, Stage IV = 8). Overall, optimal cytoreduction was achieved in 84.4% of @entity1 ; 60.0% had only microscopic residual and 24.4% had @entity66 0.1-1.0 cm. The ABC was used to facilitate cytoreduction in 31 @entity1 . Optimal disease status was achieved in 93.6% of cases in which the ABC was used compared with 64.3% for non-ABC cases (P < 0.023). ABC use was also associated with a higher rate of complete cytoreduction (74.2%) compared with non-ABC cases (28.6%, P < 0.004). Among @entity1 left with @entity66 (< or =1 cm), conversion to only microscopic residual was achieved in 79.3% of cases using the ABC and 44.4% of cases without ABC use (P < 0.044). The ABC was associated with a statistically significantly higher rate of complete cytoreduction for disease located in the lesser sac/gastrocolic ligament (90.9% vs 14.3%), abdominal peritoneum (95.5% vs 50.0%), bowel mesentery (80.0% vs 0), and pelvis (89.3% vs 50.0%). Multivariate analysis revealed that use of the ABC (P = 0.006) and disease in three or fewer anatomic regions (P = 0.014) were independent predictors of a microscopic residual surgical outcome. Complete cytoreduction was associated with a significant advantage in median progression-free survival (22.2 months) compared with @entity1 with optimal but visible (0.1-1.0 cm) @entity66 (12.3 months) and those with suboptimal (>1.0 cm) @entity66 (6.3 months, P < 0.001). Among ABC cases, the mean estimated @entity190 was 527 ml, and major @entity260 occurred in 9.7% of @entity1 . CONCLUSIONS: The ABC is a useful adjunct to conventional @entity5 reductive techniques and appears to significantly increase the feasibility of achieving both @entity66 status and complete cytoreduction of all visible @entity5 in @entity1 with macroscopic metastatic @entity43 .

Complete surgical cytoreduction of advanced @entity43 using the XXXX beam coagulator.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian carcinoma', 'epithelial ovarian carcinoma'] @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease', 'optimal disease'] @entity41 :: ('MESH:D018365', 'Disease') :: ['residual tumor'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss'] @entity260 :: ('MESH:D011183', 'Disease') :: ['postoperative complications'] @entity3503 :: ('MESH:D001128', 'Chemical') :: ['argon']
@entity3503 :: (MESH:D001128,Chemical) :: ['argon']
